Functional and biochemical basis for multiple muscarinic acetylcholine receptors

Mark Watson, Thomas W. Vickroy, William R. Roeske, Henry I. Yamamura

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


1. The novel antimuscarinic compound pirenzepine (PZ) has generated considerable interest in the basis and the implications of muscarinic acetylcholine receptor (mAChR) heterogeneity. 2. [3H]PZ has been used extensively to identify and characterize the putative M1 (high affinity for PZ) mAChR subtype, which predominates in central nervous system (CNS) and ganglia. 3. The heterogeneity sensed by PZ is not identical to the heterogeneity sensed by agonists. 4. Differences in effector coupling do not necessarily provide a simple explanation for the molecular basis of these putative M1 and M2 subtypes. 5. Therapeutic and untoward effects of muscarinic drugs may be mediated by independent mAChR subpopulations which may be pharmacologically exploited to produce more highly selective as well as efficacious new drugs.

Original languageEnglish (US)
Pages (from-to)569-574
Number of pages6
JournalProgress in Neuropsychopharmacology and Biological Psychiatry
Issue number5-6
StatePublished - 1985


  • Alzheimer's Disease
  • CNS
  • QNB
  • effector
  • muscarinic
  • pirenzepine
  • receptor

ASJC Scopus subject areas

  • Pharmacology
  • Biological Psychiatry


Dive into the research topics of 'Functional and biochemical basis for multiple muscarinic acetylcholine receptors'. Together they form a unique fingerprint.

Cite this